Latest news with #GEHealthCareTechnologiesInc
Yahoo
11-07-2025
- Business
- Yahoo
What You Need To Know Ahead of GE HealthCare Technologies' Earnings Release
Chicago, Illinois GE HealthCare Technologies Inc. (GEHC) designs medical imaging and patient-monitoring products and related equipment and services. Valued at $34.4 billion by market cap, GEHC has a leading share in the imaging and ultrasound equipment market. The company is set to announce its second-quarter results before the market opens on Wednesday, Jul. 30. Ahead of the event, analysts expect the healthcare major to deliver a profit of $0.91 per share, down 9% from $1 per share reported in the year-ago quarter. On the positive note, the company has a solid earnings surprise history. It has surpassed the Street's bottom-line estimates in each of the past four quarters. This Underdog AI Stock Just Got a New Street-High Price Target As Joby Aviation Hits a New 52-Week High, Jim Cramer Says He Won't 'Fight' the Rally Texas Just Passed Quantum Computing Legislation. How Should You Play IONQ Stock Here? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full fiscal 2025, analysts expect GEHC to deliver an EPS of $4.02, down 10.5% from $4.49 reported in the previous year. While in fiscal 2026, its earnings are expected to rebound 12.2% year-over-year to $4.51 per share. GEHC stock has observed a 1.8% dip over the past 52 weeks, performing slightly better than the Health Care Select Sector SPDR Fund's (XLV) 6.5% decline, but lagging behind the S&P 500 Index's ($SPX) 12.3% returns during the same time frame. GE Healthcare observed a solid start to the year, its stock prices gained 3.3% after the release of its Q1 results on Apr. 30. Driven by strengthening sales in the U.S., the company's organic revenues observed a notable boost; its overall sales for the quarter grew 2.7% year-over-year to $4.8 billion. Furthermore, driven by the impact of leverage, its adjusted EPS increased 12.2% year-over-year to $1.01, surpassing the consensus estimates by 11%. The stock holds a consensus 'Strong Buy' rating overall. Of the 19 analysts covering the GEHC stock, opinions include 13 'Strong Buys,' one 'Moderate Buy,' and five 'Holds.' Its mean price target of $87.16 suggests a 15.4% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Business Wire
01-07-2025
- Business
- Business Wire
GE HealthCare announces cash dividend for second quarter of 2025
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.
Yahoo
16-06-2025
- Business
- Yahoo
GEHC Stock Declines Despite Expansion in Precision Care Capabilities
GE HealthCare Technologies Inc. GEHC, on Thursday, announced the combination of its proprietary features and algorithms with MIM Encore. Per management, the software solution has been designed to handle key healthcare challenges like improving efficiency, streamlining cross-departmental communication and reducing manual workloads. GE HealthCare acquired MIM Software in 2024. The latest move is expected to be a significant milestone for GE HealthCare with respect to delivering precision care through advanced digital solutions. This, in turn, is likely to boost its Molecular Imaging & Computed Tomography (CT) business and strengthen its foothold in the niche space. Following the announcement, shares of the company lost nearly 1.6% till Friday's trading. Historically, the company has gained a high level of synergies from its partnerships. Although the latest announcement is likely to be beneficial for GEHC's top-line growth going forward, the stock declined overall. GE HealthCare currently has a market capitalization of $33.08 billion. It has an earnings yield of 5.6%, better than the industry's 0.5%. In the last reported quarter, GEHC delivered an earnings surprise of 10.9%. Per GE HealthCare, its first combined software release with MIM Encore will likely aid in enhancing digital imaging and workflow solutions across oncology, cardiology and neurology. MIM Encore, now equipped with additional GE HealthCare features and algorithms, is expected to deliver an integrated reporting experience for both positron emission tomography (PET) and SPECT (single-photon emission CT) imaging. Also, GE HealthCare's Effortless Workflow seamlessly integrates with MIM Encore, enabling clinicians to manage rising caseloads with intuitive interfaces, customizable displays and automation that can help bridge experience gaps and reduce burnout. Per a report by Grand View Research, the global molecular imaging market was valued at $8.8 billion in 2024 and is anticipated to witness a CAGR of 4.6% between 2025 and 2030. Factors like the increasing prevalence of chronic diseases, such as cancer, the therapeutic sectors, and the development of hybrid imaging systems are likely to drive the market. Given the market potential, the latest advancement in precision care is expected to provide a significant boost to GE HealthCare's business. This month, GE HealthCare and PT Kalbe Farma Tbk (Kalbe) have officially inaugurated Indonesia's first production facility dedicated to manufacturing technologically advanced CT scanners. Last month, GE HealthCare announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for clinicians now recommend considering fluoroestradiol (FES) PET for systemic staging in patients with recurrent or metastatic lobular breast cancer. The same month, GE HealthCare received the FDA's 510(k) clearance for its Aurora nuclear medicine system and Clarify DL. Shares of the company have lost 6.8% in the past year against the industry's 10.1% rise and the S&P 500's gain of 9.4%. Image Source: Zacks Investment Research Currently, GEHC carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are Hims & Hers Health, Inc. HIMS, Cencora, Inc. COR and Integer Holdings Corporation ITGR. Hims & Hers, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 36.5%. HIMS's earnings surpassed estimates in two of the trailing four quarters, missed once and broke even in the other, the average surprise being 19.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Hims & Hers' shares have surged 129.7% compared with the industry's 36.1% gain in the past year. Cencora, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.8%. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. Cencora has rallied 25.9% against the industry's 16% decline in the past year. Integer Holdings, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. Integer Holdings' shares have gained 0.9% against the industry's 14.2% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
17-05-2025
- Business
- Yahoo
Jim Cramer Says He is Not a 'Backer' of GE HealthCare Technologies (GEHC)
A caller asked if GE HealthCare Technologies Inc. (NASDAQ:GEHC) is worth another look, and in response, Cramer said: 'Okay, now you know, you're a club member, you know I sold a lot in the high 80s and then gave up on the rest. The reason I did was because it's inconsistent and too controlled by China, not America. So I am not going to be a backer. I am going to say the fabled [don't buy, don't buy, don't buy].' A radiologist in a lab examining a computed tomography scan of a patient. GE HealthCare (NASDAQ:GEHC) develops, manufactures, and markets a range of products, services, and digital tools that support the diagnosis, treatment, and monitoring of patients. The company reported a 3% year-over-year increase in revenue for the first quarter of 2025. The adjusted EBIT margin rose to 15.0% from 14.7%, and adjusted EPS increased to $1.01 from $0.90. Furthermore, free cash flow declined to $98 million, down from $274 million in the same quarter last year. While we acknowledge the potential of GEHC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GEHC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: Jim Cramer Commented on These 6 Natural Gas Players and 13 Stocks on Jim Cramer's Radar Recently Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Jim Cramer Says He is Not a 'Backer' of GE HealthCare Technologies (GEHC)
A caller asked if GE HealthCare Technologies Inc. (NASDAQ:GEHC) is worth another look, and in response, Cramer said: 'Okay, now you know, you're a club member, you know I sold a lot in the high 80s and then gave up on the rest. The reason I did was because it's inconsistent and too controlled by China, not America. So I am not going to be a backer. I am going to say the fabled [don't buy, don't buy, don't buy].' A radiologist in a lab examining a computed tomography scan of a patient. GE HealthCare (NASDAQ:GEHC) develops, manufactures, and markets a range of products, services, and digital tools that support the diagnosis, treatment, and monitoring of patients. The company reported a 3% year-over-year increase in revenue for the first quarter of 2025. The adjusted EBIT margin rose to 15.0% from 14.7%, and adjusted EPS increased to $1.01 from $0.90. Furthermore, free cash flow declined to $98 million, down from $274 million in the same quarter last year. While we acknowledge the potential of GEHC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GEHC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: Jim Cramer Commented on These 6 Natural Gas Players and 13 Stocks on Jim Cramer's Radar Recently Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
